title: Endometrin as luteal phase support in assisted reproduction.
abstract: OBJECTIVE
  To compare clinical pregnancy rate (PR) and live birth rate (LBR) between Endometrin monotherapy versus Endometrin and P in oil combination therapy in assisted reproductive technology (ART) cycles.
  
  
  METHODS
  Retrospective analysis.
  
  
  METHODS
  Large private practice.
  
  
  METHODS
  Patients undergoing autologous fresh IVF cycles, autologous frozen ET cycles, and fresh oocyte donor cycles were included for analysis.
  
  
  METHODS
  Endometrin as a single agent for luteal support, Endometrin monotherapy or Endometrin with P in oil used at least once every 3 days for luteal support, Endometrin combination therapy.
  
  
  METHODS
  Clinical PR and LBR.
  
  
  RESULTS
  A total of 1,034 ART cycles were analyzed. Endometrin monotherapy was used in 694 of 1,034 (67%) cycles and Endometrin combination therapy was used in 340 of 1,034 (33%) cycles. In all fresh cycles, clinical PR was not significantly different (IVF autologous: Endometrin monotherapy 46.9% vs. Endometrin combination therapy 55.6%; donor oocyte endometrin monotherapy 45.2% vs. Endometrin combination therapy 52.0%). Frozen ET cycles had a significantly higher clinical PR and LBR with combination therapy group compared with monotherapy (clinical PR 47.9% vs. 23.5%; LBR 37.5% vs. 17.3%).
  
  
  CONCLUSIONS
  Endometrin monotherapy was sufficient for the P component of luteal support and provided high PRs for fresh cycles in both autologous and donor oocyte cycles. Clinical PR and LBR in frozen ET cycles were significantly improved with the addition of IM P to Endometrin therapy. This may reflect the fact that lesser quality embryos are transferred in frozen ET cycles, and more intense P support is required for comparable PRs.
authors.affiliation: Fertility Centers of Illinois, Chicago, Illinois. Electronic address: eve.feinberg@integramed.com.
authors.forename: Eve C
authors.initials: EC
authors.lastname: Feinberg
authors.affiliation: Fertility Centers of Illinois, Chicago, Illinois.
authors.forename: Angeline N
authors.initials: AN
authors.lastname: Beltsos
authors.affiliation: Michigan State University, College of Human Medicine, East Lansing, Michigan.
authors.forename: Elitsa
authors.initials: E
authors.lastname: Nicolaou
authors.affiliation: Fertility Centers of Illinois, Chicago, Illinois.
authors.forename: Edward L
authors.initials: EL
authors.lastname: Marut
authors.affiliation: Fertility Centers of Illinois, Chicago, Illinois.
authors.forename: Meike L
authors.initials: ML
authors.lastname: Uhler
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000628:therapy*; D007273:Injections, Intramuscular; D050498:Live Birth; D008183:Luteal Phase / Q000187:drug effects / Q000502:physiology*; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D011247:Pregnancy; D018873:Pregnancy Rate; D011374:Progesterone / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use*; D027724:Reproductive Techniques, Assisted; D012189:Retrospective Studies; D013488:Suppositories
chemical_list: D013488:Suppositories; D011374:Progesterone